Kurma Partners

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

OxThera AB manufactures products for the treatment of primary and secondary hyperoxaluria with bacteria and enzymes. It offers Oxabact, an orally delivered composition of live bacteria to promote the removal of endogenously produced oxalate for the treatment of primary hyperoxaluria and Oxazyme, a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of dietary hyperoxaluria and prevention of kidney stones. The company was founded in 2005 and is based in Stockholm, Sweden with an additional location in Knoxville, Tennessee.

AM-Pharma B.V. is a biopharmaceutical company that develops and manufactures recombinant human alkaline phosphatase therapeutics for the treatment of acute kidney injury, inflammatory bowel disease, and hypophosphatasia. It offers recombinant human alkaline phosphatase in an injectable form for the treatment of acute kidney injury, as well as oral formulation for the treatment of ulcerative colitis. The company also offers Bovine AP, an alkaline phosphatase for the treatment of inflammatory bowel disease. AM-Pharma B.V. was founded in 2000 and is based in Bunnik, the Netherlands.

Assistance Biologique & Medicale SARL was incorporated in 2009 and is based in Venissieux, France.

BliNK Therapeutics Ltd. develops a platform to generate therapeutic and diagnostic monoclonal antibodies towards clinically relevant targets. The company was incorporated in 2011 and is based in Marlow, United Kingdom.

Urine Filtration Device manufactures device for the isolation of cancer cells from urine for diagnostic applications. The company is based in France.

Sensometrix SA develops and manufactures biometric identification software and solutions. It offers SensoBox, booster software for biometric security access systems; SensoBrain, an identification acceleration; PalmSecure, a palm vein reader; and Tango, a risk management platform for fraud prevention, detection, and investigation. The company was founded in 2006 and is headquartered in Vernier, Switzerland.

Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

Flamingo Therapeutics BV develops novel drugs for various cancers, focusing on the non-coding genome. The company is headquartered in Leuven, Belgium.

Sensome SAS develops and manufactures medical micro sensors that turns invasive vascular medical devices into connected healthcare devices. The company's AI-powered micro-sensor technology detects the composition of the blockage in the brain during stroke treatment. The company was formerly known as Instent. The company was founded in 2014 and is headquartered in Massy, France.

Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with the surface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Charles helps men regain control over their daily health concerns by starting with their personal health. The company was founded in Paris, Ile-de-France, France in 2019.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.

NaoX Technologies develops wireless headphones that listen to brain vibrations.

Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

Asceneuron SA is a biotechnology company that discovers and develops therapeutics for neurodegenerative disorders with unmet medical needs. It offers therapeutics for the treatment of progressive supranuclear palsy, orphan tauopathies, and Alzheimer’s and Parkinson’s diseases. The company was founded in 2012 and is based in Lausanne, Switzerland. Asceneuron SA operates as a subsidiary of Merck KGaA.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

Talix provides risk adjustment, quality and oncology solutions to help providers, payers and life science organizations succeed in value-based healthcare. Our leading-edge SaaS applications leverage purpose built NLP, machine learning and advanced patient data analytics to transform complex data into actionable intelligence that drives improved efficiency and accuracy—leading to better patient outcomes, more accurate reimbursements and reduced costs.

KDx Acceleration SA offers virtual accelerator for projects. The company was incorporated in 2015 and is based in Paris, France.

Instent SAS develops a novel smart stent with remote and non-invasive in situ monitoring capabilities. The company’s stent enables doctors to anticipate stent-related complications and tailor the follow-up treatment to the needs of the individual patient. Instent SAS was founded in 2014 and is based in Paris, France.

Byond SAS develops artificial intelligence based solutions for medical biology. Its solutions help clinical biologists and doctors in their daily tasks. The company's tools offer information to patients and relevant to physicians, enabling medical biology laboratories to interpret and diagnose in a personalized way. Byond SAS was founded in 2019 and is headquartered in Marseille, France with additional offices in Paris and Marseille, France.

Horama SAS focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases. Its gene therapy products target retinal dystrophies and retinopathies. The company was founded in 2014 and is headquartered in Paris, France.

Sensome SAS develops and manufactures medical micro sensors that turns invasive vascular medical devices into connected healthcare devices. The company's AI-powered micro-sensor technology detects the composition of the blockage in the brain during stroke treatment. The company was formerly known as Instent. The company was founded in 2014 and is headquartered in Massy, France.

Horama SAS focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases. Its gene therapy products target retinal dystrophies and retinopathies. The company was founded in 2014 and is headquartered in Paris, France.

Arkhn is a platform specialist in healthcare data interoperability. Arkhn tackles the issue of accessing healthcare data.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

Sensome SAS develops and manufactures medical micro sensors that turns invasive vascular medical devices into connected healthcare devices. The company's AI-powered micro-sensor technology detects the composition of the blockage in the brain during stroke treatment. The company was formerly known as Instent. The company was founded in 2014 and is headquartered in Massy, France.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

DEEPULL DIAGNOSTICS LIMITED COMPANY engages in developing a system for the early diagnosis of sepsis. Its products identifies pathogens and offers the antibiogram, as well as uses the data and learns about the patient’s immunological and functional status. DEEPULL DIAGNOSTICS LIMITED COMPANY was incorporated in 2019 and is based in Barcelona, Spain.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Cardiologs is a medical technology company that uses medical-grade AI and cloud technology, transforming cardiac diagnostics. The company's product, The Cardiologs ECG Analysis Solution is built on a proprietary database of more than 1,450,000 recordings and is supported by a number of clinical publications that demonstrate leading diagnostic performance. It is powered by deep learning technology to receive regulatory clearance. Founded in 2014, Cardiologs partners with clinicians and healthcare practitioners to realize the vision of making expert cardiac diagnostics scalable, and accessible to everyone. Is is headquartered in Paris, France.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with the surface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Cardiologs is a medical technology company that uses medical-grade AI and cloud technology, transforming cardiac diagnostics. The company's product, The Cardiologs ECG Analysis Solution is built on a proprietary database of more than 1,450,000 recordings and is supported by a number of clinical publications that demonstrate leading diagnostic performance. It is powered by deep learning technology to receive regulatory clearance. Founded in 2014, Cardiologs partners with clinicians and healthcare practitioners to realize the vision of making expert cardiac diagnostics scalable, and accessible to everyone. Is is headquartered in Paris, France.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.

Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.

BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement and analysis of the pain by facial, vocal and postural recognition.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

Lucine develops mobile health application that measures, analyzes, and relieves pain at home. The company is based in France.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.

Feetme SAS develops insoles that map foot pressure in real time for diabetic patients. Its insoles are made of pressure sensors that allow patients and doctors to visualize a detailed pressure map of the feet, as well as provide warning to patients if a change in the plantar pressure is detected. The company was incorporated in 2013 and is based in Paris, France.

Amolyt Pharma Inc. engages in the development of therapeutic peptides for endocrine and metabolic diseases. It offers AZP-3601 as a treatment of hypoparathyroidism; and AZP-3404, a therapeutic peptide to regulate the body’s fat and glucose metabolism. Amolyt Pharma Inc. was incorporated in 2019 and is based in Newton, Massachusetts with an additional office in Ecully, France.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.